

Leverett

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	2.2	nc	(nc-nc)	Male	2	1.4	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.4	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	7	7.2	97.4	(39.0-200.7)	Female	1	0.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	2	3.0	nc	(nc-nc)	Female	2	0.7	nc	(nc-nc)
Female	2	2.1	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	1	0.6	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male				
Male	0	0.2	nc	(nc-nc)	Female	13	9.1	142.2	(75.6-243.1)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	0	1.2	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
Female	2	0.5	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male				
Male	0	0.4	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	0	0.7	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Female				
Male	1	0.6	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	1	4.1	nc	(nc-nc)	Female	29	30.6	94.7	(63.4-136.0)
Female	5	2.9	173.4	(55.9-404.7)	Female	21	22.8	92.0	(56.9-140.6)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Lexington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	43	44.2	97.3	(70.4-131.1)	Male	37	25.8	143.5	(101.0-197.8)
Female	18	16.7	107.5	(63.7-170.0)	Female	29	20.2	143.6	(96.1-206.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	7	7.6	92.5	(37.1-190.6)	Male	10	6.7	148.7	(71.2-273.5)
Female	6	6.4	94.3	(34.4-205.2)	Female	6	5.3	113.2	(41.3-246.5)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	1.3	nc	(nc-nc)	Male	15	22.5	66.8	(37.4-110.2)
Female	160	152.0	105.3	(89.6-122.9)	Female	16	20.9	76.5	(43.7-124.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	5.6	nc	(nc-nc)	Male	13	15.5	84.0	(44.7-143.7)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	39	57.5	67.8	(48.2-92.7)	Female	13	15.5	83.7	(44.5-143.1)
Female	41	58.9	69.6	(49.9-94.4)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	8	13.3	60.1	(25.9-118.5)
Male	8	11.0	72.5	(31.2-142.9)	Female	8	14.6	54.7	(23.5-107.7)
Female	3	3.2	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	168	156.3	107.5	(91.8-125.0)
Male	2	2.7	nc	(nc-nc)	<u>Stomach</u>				
Female	3	2.1	nc	(nc-nc)	Male	3	10.2	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	7	6.6	106.1	(42.5-218.6)
Male	17	20.4	83.5	(48.6-133.8)	<u>Testis</u>				
Female	6	12.7	47.4	(17.3-103.2)	Male	2	3.7	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	6.5	nc	(nc-nc)	Male	8	6.5	123.0	(53.0-242.4)
Female	0	1.9	nc	(nc-nc)	Female	25	20.3	123.3	(79.7-182.0)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	18	14.3	125.9	(74.6-199.0)	Female	23	33.8	68.1	(43.2-102.3)
Female	16	11.3	142.2	(81.2-231.0)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	479	558.4	85.8	(78.3-93.8)
Male	6	10.1	59.4	(21.7-129.2)	Female	489	543.6	90.0	(82.2-98.3)
Female	3	3.8	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	41	79.2	51.8	(37.1-70.2)					
Female	49	78.9	62.1	(46.0-82.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Leyden

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.8	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	2	0.5	nc	(nc-nc)
Female	2	2.9	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	2	1.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	1	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male				
Male	0	0.1	nc	(nc-nc)	Female	6	3.3	180.2	(65.8-392.3)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	0	0.5	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male				
Male	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	0	0.3	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Female				
Male	0	0.2	nc	(nc-nc)	Male	2	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	1	1.4	nc	(nc-nc)	Female	13	11.4	114.4	(60.8-195.6)
Female	0	1.1	nc	(nc-nc)	Female	7	9.1	77.2	(30.9-159.1)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Lincoln

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	7.9	nc	(nc-nc)	Male	6	5.1	118.0	(43.1-256.9)
Female	0	2.5	nc	(nc-nc)	Female	5	3.9	127.4	(41.0-297.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	1.7	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	0	1.3	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	5	4.4	114.1	(36.8-266.3)
Female	35	27.7	126.6	(88.1-176.0)	Female	1	3.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.2	nc	(nc-nc)	Male	5	3.1	162.6	(52.4-379.4)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	8	10.6	75.4	(32.5-148.7)	Female	0	2.7	nc	(nc-nc)
Female	6	8.7	69.1	(25.2-150.4)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	2	2.1	nc	(nc-nc)	Male	29	29.6	97.9	(65.5-140.6)
Female	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	0	0.7	nc	(nc-nc)	Male	2	1.2	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	3	4.0	nc	(nc-nc)	Female	6	6.1	98.4	(35.9-214.1)
Female	6	2.2	273.8	(100.0-595.9)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Leukemia</u>				
Male	0	1.2	nc	(nc-nc)	Male	3	2.8	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	2	1.9	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Lung and Bronchus</u>				
Male	2	2.0	nc	(nc-nc)	Male	6	14.6	41.2	(15.1-89.7)
Female	0	0.6	nc	(nc-nc)	Female	13	12.7	102.3	(54.4-175.0)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Littleton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	9	8.9	100.6	(45.9-191.0)	Male	9	5.9	153.5	(70.0-291.4)
Female	3	3.2	nc	(nc-nc)	Female	3	4.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	1.8	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	1	1.5	nc	(nc-nc)	Female	2	1.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	8	5.0	160.0	(68.9-315.4)
Female	34	32.9	103.2	(71.5-144.3)	Female	6	4.2	143.1	(52.3-311.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.5	nc	(nc-nc)	Male	0	3.6	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	14	12.1	115.5	(63.1-193.9)	Female	3	3.3	nc	(nc-nc)
Female	11	11.2	98.3	(49.0-176.0)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	3	2.8	nc	(nc-nc)
Male	1	2.4	nc	(nc-nc)	Female	1	2.7	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	37	33.7	109.8	(77.3-151.4)
Male	2	0.8	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.6	nc	(nc-nc)	Male	1	2.1	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	1.2	nc	(nc-nc)
Male	3	4.6	nc	(nc-nc)	<u>Testis</u>				
Female	0	2.6	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	1.4	nc	(nc-nc)	Male	2	1.7	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	4	5.4	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	3	3.1	nc	(nc-nc)	Female	6	7.3	82.6	(30.2-179.9)
Female	5	2.4	212.0	(68.3-494.8)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	115	120.6	95.4	(78.7-114.5)
Male	0	2.3	nc	(nc-nc)	Female	100	113.1	88.4	(71.9-107.5)
Female	0	0.7	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	8	16.3	49.0	(21.1-96.5)					
Female	10	15.4	65.1	(31.2-119.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Longmeadow

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	18	22.2	81.2	(48.1-128.3)	Male	19	13.1	145.3	(87.4-226.9)
Female	6	8.3	72.4	(26.5-157.7)	Female	17	10.2	167.3	(97.4-267.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	3.8	nc	(nc-nc)	Male	3	3.4	nc	(nc-nc)
Female	2	3.2	nc	(nc-nc)	Female	1	2.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.7	nc	(nc-nc)	Male	14	11.3	123.5	(67.4-207.2)
Female	81	75.6	107.1	(85.1-133.1)	Female	8	10.5	76.5	(32.9-150.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	2.8	nc	(nc-nc)	Male	2	8.0	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	26	29.2	89.1	(58.2-130.6)	Female	10	7.8	128.5	(61.5-236.4)
Female	23	29.7	77.5	(49.1-116.4)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	2	6.7	nc	(nc-nc)
Male	7	5.6	125.4	(50.2-258.3)	Female	6	7.3	82.5	(30.1-179.5)
Female	1	1.6	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	89	79.6	111.8	(89.8-137.6)
Male	1	1.4	nc	(nc-nc)	<u>Stomach</u>				
Female	1	1.1	nc	(nc-nc)	Male	3	5.1	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	3.3	nc	(nc-nc)
Male	13	10.3	126.8	(67.4-216.8)	<u>Testis</u>				
Female	8	6.3	127.8	(55.0-251.8)	Male	2	1.9	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	3.3	nc	(nc-nc)	Male	4	3.3	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	9	10.2	88.2	(40.3-167.5)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	8	7.3	110.2	(47.5-217.2)	Female	15	16.9	88.9	(49.7-146.6)
Female	2	5.7	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	260	282.4	92.1	(81.2-104.0)
Male	3	5.2	nc	(nc-nc)	Female	238	270.8	87.9	(77.1-99.8)
Female	0	1.9	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	25	39.4	63.4	(41.0-93.6)					
Female	29	38.5	75.3	(50.4-108.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Lowell

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	88	83.3	105.7	(84.7-130.2)	Male	18	56.9	31.6	(18.7-50.0)
Female	34	34.7	98.0	(67.8-136.9)	Female	21	50.1	41.9	(25.9-64.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	16	19.3	83.0	(47.4-134.8)	Male	10	13.2	75.6	(36.2-139.0)
Female	13	16.4	79.2	(42.1-135.5)	Female	15	10.9	137.2	(76.8-226.4)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	6	2.5	235.6	(86.0-512.9)	Male	46	48.7	94.4	(69.1-125.9)
Female	260	334.8	77.7	(68.5-87.7)	Female	42	45.5	92.3	(66.5-124.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	16	15.3	104.9	(59.9-170.3)	Male	63	33.5	188.1	(144.5-240.6)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	140	113.0	123.9	(104.3-146.3)	Female	37	34.3	107.8	(75.9-148.6)
Female	134	121.2	110.6	(92.6-131.0)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	23	25.6	89.7	(56.9-134.6)
Male	23	22.1	104.2	(66.0-156.3)	Female	27	29.9	90.3	(59.5-131.3)
Female	8	6.6	121.5	(52.3-239.4)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	245	313.5	78.1	(68.7-88.6)
Male	10	10.1	98.9	(47.3-181.8)	<u>Stomach</u>				
Female	6	7.9	75.7	(27.6-164.7)	Male	17	19.7	86.3	(50.2-138.2)
<u>Kidney & Renal Pelvis</u>					Female	10	13.6	73.7	(35.3-135.6)
Male	48	42.9	111.8	(82.4-148.2)	<u>Testis</u>				
Female	36	27.8	129.7	(90.8-179.6)	Male	11	17.8	61.8	(30.8-110.5)
<u>Larynx</u>					<u>Thyroid</u>				
Male	21	13.2	159.0	(98.4-243.1)	Male	16	17.3	92.4	(52.8-150.0)
Female	5	4.0	123.9	(39.9-289.1)	Female	58	57.8	100.3	(76.2-129.7)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	43	31.6	136.1	(98.5-183.3)	Female	74	73.1	101.2	(79.4-127.0)
Female	26	26.2	99.2	(64.8-145.4)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	1164	1146.8	101.5	(95.7-107.5)
Male	41	21.2	193.6	(138.9-262.6)	Female	1140	1198.6	95.1	(89.7-100.8)
Female	11	8.1	136.3	(67.9-243.8)					
<u>Lung and Bronchus</u>									
Male	186	152.9	121.7	(104.8-140.5)					
Female	180	166.2	108.3	(93.1-125.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Ludlow

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	18	25.3	71.2	(42.2-112.5)	Male	7	16.2	43.1	(17.3-88.9)
Female	7	9.3	75.6	(30.3-155.7)	Female	7	12.1	57.9	(23.2-119.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	5.0	nc	(nc-nc)	Male	1	4.0	nc	(nc-nc)
Female	8	3.8	210.0	(90.4-413.8)	Female	3	3.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.8	nc	(nc-nc)	Male	6	13.8	43.4	(15.8-94.4)
Female	80	87.3	91.6	(72.6-114.0)	Female	10	11.8	84.4	(40.4-155.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	3.5	nc	(nc-nc)	Male	5	9.8	51.1	(16.5-119.2)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	30	33.7	89.0	(60.0-127.0)	Female	4	8.9	nc	(nc-nc)
Female	28	31.7	88.3	(58.7-127.6)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	9	7.8	115.9	(52.9-220.1)
Male	3	6.6	nc	(nc-nc)	Female	9	8.0	112.7	(51.4-214.0)
Female	1	1.8	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	98	95.5	102.6	(83.3-125.0)
Male	5	2.4	211.2	(68.1-492.9)	<u>Stomach</u>				
Female	1	1.5	nc	(nc-nc)	Male	9	5.9	152.7	(69.7-289.8)
<u>Kidney & Renal Pelvis</u>					Female	4	3.5	nc	(nc-nc)
Male	16	12.5	127.6	(72.9-207.2)	<u>Testis</u>				
Female	4	7.3	nc	(nc-nc)	Male	5	4.0	126.0	(40.6-294.0)
<u>Larynx</u>					<u>Thyroid</u>				
Male	4	4.0	nc	(nc-nc)	Male	5	4.6	108.9	(35.1-254.1)
Female	0	1.1	nc	(nc-nc)	Female	10	13.0	76.7	(36.7-141.0)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	12	8.7	138.6	(71.6-242.2)	Female	11	19.6	56.2	(28.0-100.5)
Female	3	6.3	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	317	338.6	93.6	(83.6-104.5)
Male	8	6.2	128.3	(55.3-252.9)	Female	235	310.2	75.7	(66.4-86.1)
Female	0	2.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	51	46.4	109.8	(81.8-144.4)					
Female	25	45.4	55.1	(35.6-81.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Lunenburg

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	14	10.6	132.1	(72.2-221.6)	Male	9	7.1	127.2	(58.0-241.5)
Female	2	3.5	nc	(nc-nc)	Female	3	5.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	2.2	nc	(nc-nc)	Male	3	1.7	nc	(nc-nc)
Female	4	1.6	nc	(nc-nc)	Female	4	1.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	2	6.0	nc	(nc-nc)
Female	34	38.7	87.9	(60.8-122.8)	Female	5	4.7	107.5	(34.6-250.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.7	nc	(nc-nc)	Male	4	4.4	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	9	14.6	61.7	(28.2-117.2)	Female	2	3.8	nc	(nc-nc)
Female	8	12.1	66.3	(28.5-130.6)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	4	3.3	nc	(nc-nc)
Male	1	2.9	nc	(nc-nc)	Female	6	3.0	202.2	(73.8-440.0)
Female	2	0.7	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	46	41.4	111.1	(81.4-148.2)
Male	0	0.9	nc	(nc-nc)	<u>Stomach</u>				
Female	3	0.7	nc	(nc-nc)	Male	3	2.5	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	1.3	nc	(nc-nc)
Male	4	5.6	nc	(nc-nc)	<u>Testis</u>				
Female	2	3.0	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	3	1.7	nc	(nc-nc)	Male	0	2.1	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	6	6.4	94.3	(34.4-205.3)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	6	3.7	161.3	(58.9-351.0)	Female	10	8.6	116.2	(55.6-213.8)
Female	3	2.5	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	138	145.9	94.6	(79.5-111.8)
Male	2	2.8	nc	(nc-nc)	Female	120	128.8	93.2	(77.3-111.4)
Female	1	0.8	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	23	19.6	117.2	(74.3-175.8)					
Female	18	17.4	103.7	(61.4-163.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Lynn

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	91	84.5	107.6	(86.7-132.2)	Male	39	54.4	71.7	(51.0-98.1)
Female	38	32.6	116.6	(82.5-160.1)	Female	29	45.9	63.1	(42.3-90.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	16	17.9	89.6	(51.2-145.5)	Male	18	13.2	136.8	(81.0-216.2)
Female	18	15.0	119.9	(71.0-189.4)	Female	7	10.3	67.9	(27.2-139.9)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	4	2.5	nc	(nc-nc)	Male	50	47.0	106.4	(78.9-140.2)
Female	275	314.2	87.5	(77.5-98.5)	Female	47	42.5	110.6	(81.3-147.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	18	13.7	130.9	(77.6-207.0)	Male	44	31.9	137.9	(100.2-185.1)
Female					Female	20	15.9	126.2	(77.0-194.9)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	104	112.5	92.4	(75.5-112.0)	Female	32	32.1	99.6	(68.1-140.5)
Female	108	113.5	95.1	(78.0-114.8)					
<u>Esophagus</u>					<u>Pancreas</u>				
Male	30	21.7	138.3	(93.3-197.4)	Male	24	25.7	93.4	(59.8-139.0)
Female	7	6.2	113.3	(45.4-233.4)	Female	37	28.1	131.5	(92.6-181.2)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	10	8.6	116.6	(55.8-214.4)	Male	260	306.3	84.9	(74.9-95.8)
Female	5	6.8	73.1	(23.6-170.6)					
<u>Kidney & Renal Pelvis</u>					<u>Stomach</u>				
Male	42	41.4	101.3	(73.0-137.0)	Male	35	19.8	176.7	(123.1-245.8)
Female	39	26.0	149.9	(106.6-204.9)	Female	24	12.6	189.8	(121.6-282.5)
<u>Larynx</u>					<u>Testis</u>				
Male	13	12.9	100.8	(53.6-172.3)	Male	8	14.4	55.5	(23.9-109.5)
Female	4	3.8	nc	(nc-nc)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	41	30.7	133.4	(95.7-181.0)	Male	10	15.5	64.3	(30.8-118.3)
Female	32	24.2	132.0	(90.3-186.4)	Female	45	52.0	86.5	(63.1-115.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	27	20.4	132.1	(87.0-192.2)	Female	83	69.4	119.7	(95.3-148.3)
Female	9	7.6	119.1	(54.3-226.1)					
<u>Lung and Bronchus</u>					<u>All Sites / Types</u>				
Male	173	152.9	113.2	(96.9-131.4)	Male	1143	1121.9	101.9	(96.1-108.0)
Female	192	156.7	122.5	(105.8-141.2)	Female	1176	1119.8	105.0	(99.1-111.2)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Lynnfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	17	17.4	97.8	(56.9-156.6)	Male	14	10.2	136.9	(74.8-229.7)
Female	6	5.5	108.8	(39.7-236.8)	Female	10	7.1	140.2	(67.1-257.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	3.0	nc	(nc-nc)	Male	2	2.7	nc	(nc-nc)
Female	1	2.2	nc	(nc-nc)	Female	0	1.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.5	nc	(nc-nc)	Male	7	8.9	78.9	(31.6-162.7)
Female	63	53.8	117.0	(89.9-149.7)	Female	7	7.1	99.1	(39.7-204.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	2.0	nc	(nc-nc)	Male	1	6.2	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	23	22.7	101.3	(64.2-152.0)	Female	8	5.4	147.8	(63.6-291.2)
Female	14	18.9	74.0	(40.4-124.1)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	5	5.3	94.6	(30.5-220.8)
Male	5	4.4	112.7	(36.3-263.1)	Female	2	4.7	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	70	63.4	110.4	(86.1-139.5)
Male	2	1.1	nc	(nc-nc)	<u>Stomach</u>				
Female	1	0.8	nc	(nc-nc)	Male	1	4.0	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	3	2.1	nc	(nc-nc)
Male	6	8.1	74.0	(27.0-161.0)	<u>Testis</u>				
Female	5	4.4	112.6	(36.3-262.8)	Male	1	1.5	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	4	2.6	nc	(nc-nc)	Male	6	2.6	232.3	(84.8-505.6)
Female	1	0.7	nc	(nc-nc)	Female	10	7.6	132.3	(63.3-243.3)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	12	5.6	213.3	(110.1-372.6)	Female	12	12.2	98.0	(50.6-171.1)
Female	4	3.7	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	222	222.7	99.7	(87.0-113.7)
Male	0	4.1	nc	(nc-nc)	Female	195	187.1	104.2	(90.1-119.9)
Female	1	1.3	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	22	31.5	69.9	(43.8-105.8)					
Female	23	27.2	84.4	(53.5-126.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Malden

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	68	58.3	116.7	(90.6-148.0)	Male	25	37.4	66.9	(43.3-98.7)
Female	24	23.1	104.0	(66.6-154.8)	Female	21	31.8	66.1	(40.9-101.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	13	11.6	111.8	(59.5-191.3)	Male	8	9.1	88.3	(38.0-174.0)
Female	8	9.9	80.9	(34.8-159.4)	Female	3	7.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.8	nc	(nc-nc)	Male	29	31.9	90.9	(60.8-130.5)
Female	201	217.5	92.4	(80.1-106.1)	Female	20	29.7	67.4	(41.2-104.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	12	9.5	126.2	(65.1-220.5)	Male	30	21.7	138.2	(93.2-197.4)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	94	77.3	121.7	(98.3-148.9)	Female	16	22.3	71.8	(41.0-116.7)
Female	76	80.1	94.9	(74.8-118.8)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	17	17.6	96.4	(56.1-154.3)
Male	12	14.9	80.6	(41.6-140.8)	Female	9	19.9	45.3	(20.7-86.0)
Female	5	4.4	114.0	(36.7-266.0)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	180	213.0	84.5	(72.6-97.8)
Male	4	5.6	nc	(nc-nc)	<u>Stomach</u>				
Female	5	4.5	112.3	(36.2-262.1)	Male	14	13.6	102.7	(56.1-172.3)
<u>Kidney & Renal Pelvis</u>					Female	7	9.0	78.1	(31.3-160.9)
Male	22	28.3	77.7	(48.7-117.7)	<u>Testis</u>				
Female	15	18.1	82.9	(46.3-136.7)	Male	7	10.0	69.8	(28.0-143.8)
<u>Larynx</u>					<u>Thyroid</u>				
Male	5	8.9	56.1	(18.1-131.0)	Male	10	10.7	93.7	(44.9-172.3)
Female	1	2.7	nc	(nc-nc)	Female	36	35.7	100.9	(70.7-139.7)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	17	20.3	83.9	(48.9-134.4)	Female	38	48.1	79.0	(55.9-108.5)
Female	14	16.3	85.6	(46.8-143.7)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	764	771.0	99.1	(92.2-106.4)
Male	28	13.9	201.4	(133.8-291.1)	Female	704	779.7	90.3	(83.7-97.2)
Female	11	5.3	208.5	(103.9-373.1)					
<u>Lung and Bronchus</u>									
Male	114	105.7	107.8	(88.9-129.5)					
Female	112	110.5	101.3	(83.4-121.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Manchester by the Sea

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	7.3	68.5	(22.1-159.8)	Male	7	4.5	155.3	(62.2-320.0)
Female	1	2.6	nc	(nc-nc)	Female	9	3.4	263.7	(120.3-500.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	1.3	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	2	3.8	nc	(nc-nc)
Female	39	25.9	150.7	(107.2-206.0)	Female	4	3.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.0	nc	(nc-nc)	Male	6	2.9	209.0	(76.3-454.9)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	11	9.8	112.5	(56.1-201.3)	Female	2	2.6	nc	(nc-nc)
Female	12	8.9	134.5	(69.4-234.9)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	1	2.3	nc	(nc-nc)
Male	3	2.0	nc	(nc-nc)	Female	1	2.2	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	21	28.8	72.9	(45.1-111.5)
Male	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.4	nc	(nc-nc)	Male	2	1.7	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	1.0	nc	(nc-nc)
Male	1	3.6	nc	(nc-nc)	<u>Testis</u>				
Female	1	2.1	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	1.2	nc	(nc-nc)	Male	3	1.2	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	1	3.7	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	3	2.4	nc	(nc-nc)	Female	4	6.0	nc	(nc-nc)
Female	5	1.7	286.8	(92.4-669.3)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	93	97.7	95.2	(76.8-116.6)
Male	3	1.8	nc	(nc-nc)	Female	94	88.9	105.7	(85.4-129.4)
Female	0	0.6	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	8	13.6	59.0	(25.4-116.3)					
Female	5	12.7	39.5	(12.7-92.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Mansfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	16	14.0	114.1	(65.2-185.4)	Male	11	11.1	99.2	(49.5-177.5)
Female	11	5.0	220.5	(109.9-394.5)	Female	15	9.9	151.0	(84.5-249.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	4.0	nc	(nc-nc)	Male	3	2.4	nc	(nc-nc)
Female	3	3.1	nc	(nc-nc)	Female	2	1.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	9	9.3	96.4	(44.0-183.0)
Female	58	63.0	92.0	(69.9-118.9)	Female	6	7.3	82.6	(30.2-179.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	3.5	nc	(nc-nc)	Male	8	6.7	119.5	(51.5-235.5)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	18	20.3	88.5	(52.4-139.9)	Female	5	6.0	82.8	(26.7-193.3)
Female	23	18.0	127.7	(80.9-191.6)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	6	4.5	134.5	(49.1-292.7)
Male	10	4.0	249.6	(119.5-459.0)	Female	7	4.3	163.8	(65.6-337.5)
Female	0	0.9	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	58	55.2	105.1	(79.8-135.9)
Male	1	2.1	nc	(nc-nc)	<u>Stomach</u>				
Female	1	1.6	nc	(nc-nc)	Male	2	3.5	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	2.0	nc	(nc-nc)
Male	8	8.3	96.1	(41.4-189.4)	<u>Testis</u>				
Female	8	4.7	171.9	(74.0-338.8)	Male	6	3.9	153.1	(55.9-333.2)
<u>Larynx</u>					<u>Thyroid</u>				
Male	5	2.4	209.2	(67.4-488.2)	Male	4	3.8	nc	(nc-nc)
Female	2	0.7	nc	(nc-nc)	Female	20	13.4	149.7	(91.4-231.2)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	7	5.9	118.1	(47.3-243.4)	Female	13	13.1	99.3	(52.8-169.9)
Female	6	4.4	135.0	(49.3-293.8)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	214	207.9	102.9	(89.6-117.7)
Male	6	4.1	145.3	(53.1-316.2)	Female	230	206.5	111.4	(97.5-126.8)
Female	2	1.3	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	25	26.0	96.2	(62.2-142.0)					
Female	31	24.5	126.5	(85.9-179.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Marblehead

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	29	26.9	107.9	(72.3-155.0)	Male	30	16.5	181.9	(122.7-259.7)
Female	11	9.4	116.8	(58.2-208.9)	Female	29	12.8	226.5	(151.6-325.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	4.9	102.0	(32.9-238.1)	Male	4	4.2	nc	(nc-nc)
Female	8	4.0	202.5	(87.2-399.0)	Female	0	3.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.8	nc	(nc-nc)	Male	16	14.1	113.2	(64.7-183.9)
Female	101	94.7	106.7	(86.9-129.7)	Female	15	12.2	123.1	(68.9-203.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	7	3.8	185.3	(74.2-381.8)	Male	8	10.2	78.1	(33.6-154.0)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	40	35.8	111.8	(79.8-152.2)	Female	6	9.5	63.4	(23.2-138.0)
Female	39	33.0	118.3	(84.1-161.7)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	6	8.2	72.7	(26.6-158.3)
Male	1	7.0	nc	(nc-nc)	Female	8	8.2	98.1	(42.3-193.4)
Female	2	1.8	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	111	101.3	109.6	(90.1-131.9)
Male	1	1.8	nc	(nc-nc)	<u>Stomach</u>				
Female	1	1.4	nc	(nc-nc)	Male	2	6.2	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	3	3.6	nc	(nc-nc)
Male	14	13.0	107.3	(58.6-180.0)	<u>Testis</u>				
Female	6	7.6	78.6	(28.7-171.0)	Male	4	2.7	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	4.2	nc	(nc-nc)	Male	4	4.4	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	Female	6	14.0	42.8	(15.6-93.2)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	10	8.9	112.3	(53.8-206.6)	Female	14	21.2	66.1	(36.1-110.9)
Female	8	6.5	122.6	(52.8-241.7)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	361	353.4	102.2	(91.9-113.3)
Male	7	6.6	105.8	(42.4-218.0)	Female	345	326.2	105.8	(94.9-117.5)
Female	4	2.2	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	27	49.0	55.1	(36.3-80.2)					
Female	40	45.8	87.3	(62.4-118.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Marion

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	7.9	nc	(nc-nc)	Male	6	4.7	128.6	(47.0-280.0)
Female	4	2.7	nc	(nc-nc)	Female	4	3.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.4	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	3	4.0	nc	(nc-nc)
Female	24	25.7	93.5	(59.9-139.2)	Female	7	3.5	202.7	(81.2-417.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.0	nc	(nc-nc)	Male	1	2.8	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	3	10.4	nc	(nc-nc)	Female	3	2.6	nc	(nc-nc)
Female	11	9.5	116.0	(57.8-207.6)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	4	2.4	nc	(nc-nc)
Male	2	2.0	nc	(nc-nc)	Female	1	2.4	nc	(nc-nc)
Female	2	0.5	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	24	29.0	82.8	(53.0-123.2)
Male	1	0.5	nc	(nc-nc)	<u>Stomach</u>				
Female	1	0.4	nc	(nc-nc)	Male	1	1.8	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	1.0	nc	(nc-nc)
Male	1	3.7	nc	(nc-nc)	<u>Testis</u>				
Female	0	2.1	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	1.2	nc	(nc-nc)	Male	4	1.2	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	3	3.5	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	2.6	nc	(nc-nc)	Female	7	5.9	119.2	(47.7-245.5)
Female	0	1.8	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	71	101.6	69.9	(54.6-88.2)
Male	0	1.8	nc	(nc-nc)	Female	86	90.7	94.8	(75.8-117.1)
Female	2	0.6	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	12	14.4	83.4	(43.1-145.8)					
Female	11	13.2	83.1	(41.4-148.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Marlborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	39	35.8	109.0	(77.5-149.0)	Male	15	24.0	62.4	(34.9-102.9)
Female	13	13.7	94.9	(50.5-162.4)	Female	17	19.8	85.8	(49.9-137.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	8	7.7	104.5	(45.0-206.0)	Male	5	5.7	87.9	(28.3-205.1)
Female	9	6.2	145.8	(66.5-276.8)	Female	2	4.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.1	nc	(nc-nc)	Male	20	20.4	97.8	(59.7-151.1)
Female	131	136.5	96.0	(80.3-113.9)	Female	16	17.9	89.4	(51.1-145.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	9	6.1	146.9	(67.0-278.9)	Male	14	14.4	97.4	(53.2-163.4)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	36	48.7	74.0	(51.8-102.4)	Female	14	13.8	101.7	(55.5-170.6)
Female	36	48.0	74.9	(52.5-103.8)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	5	11.0	45.3	(14.6-105.6)
Male	8	9.5	84.1	(36.2-165.7)	Female	16	11.8	135.7	(77.5-220.4)
Female	6	2.6	231.4	(84.5-503.6)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	118	134.6	87.7	(72.6-105.0)
Male	7	3.6	192.3	(77.0-396.2)	<u>Stomach</u>				
Female	4	2.7	nc	(nc-nc)	Male	5	8.5	59.0	(19.0-137.7)
<u>Kidney & Renal Pelvis</u>					Female	4	5.4	nc	(nc-nc)
Male	20	18.4	108.9	(66.5-168.3)	<u>Testis</u>				
Female	10	11.0	90.7	(43.4-166.7)	Male	6	6.5	92.5	(33.8-201.3)
<u>Larynx</u>					<u>Thyroid</u>				
Male	3	5.7	nc	(nc-nc)	Male	12	7.1	168.4	(86.9-294.1)
Female	1	1.6	nc	(nc-nc)	Female	29	22.9	126.8	(84.9-182.0)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	14	12.9	108.9	(59.5-182.7)	Female	28	30.1	93.0	(61.8-134.5)
Female	8	10.0	79.9	(34.4-157.4)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	427	487.1	87.7	(79.5-96.4)
Male	12	9.1	132.0	(68.1-230.6)	Female	479	478.1	100.2	(91.4-109.6)
Female	3	3.2	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	65	65.3	99.5	(76.8-126.9)					
Female	73	65.5	111.4	(87.3-140.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Marshfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	28	22.7	123.4	(82.0-178.4)	Male	32	15.9	200.9	(137.4-283.6)
Female	13	8.0	162.5	(86.5-278.0)	Female	13	13.0	100.0	(53.2-171.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	5.1	nc	(nc-nc)	Male	5	3.7	133.4	(43.0-311.3)
Female	3	4.0	nc	(nc-nc)	Female	7	2.6	267.2	(107.1-550.6)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.7	nc	(nc-nc)	Male	20	13.3	150.2	(91.7-232.0)
Female	111	93.1	119.3	(98.1-143.6)	Female	14	10.9	128.5	(70.2-215.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	4.1	nc	(nc-nc)	Male	12	10.2	117.7	(60.7-205.6)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	34	31.8	107.0	(74.1-149.5)	Female	12	9.1	132.6	(68.4-231.6)
Female	32	27.5	116.3	(79.5-164.2)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	6	7.2	83.1	(30.4-180.9)
Male	13	6.5	201.2	(107.0-344.0)	Female	7	6.8	103.4	(41.4-213.0)
Female	0	1.5	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	139	94.5	147.1	(123.7-173.7)
Male	2	2.2	nc	(nc-nc)	<u>Stomach</u>				
Female	4	1.7	nc	(nc-nc)	Male	2	5.4	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	4	2.9	nc	(nc-nc)
Male	12	12.5	96.1	(49.6-167.8)	<u>Testis</u>				
Female	1	7.2	nc	(nc-nc)	Male	7	3.7	187.1	(75.0-385.6)
<u>Larynx</u>					<u>Thyroid</u>				
Male	4	3.9	nc	(nc-nc)	Male	1	4.8	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	Female	14	15.9	88.3	(48.2-148.2)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	12	8.3	144.1	(74.4-251.8)	Female	25	21.0	119.2	(77.1-176.0)
Female	7	6.0	116.3	(46.6-239.6)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	427	325.3	131.2	(119.1-144.3)
Male	7	6.4	109.3	(43.8-225.1)	Female	362	305.8	118.4	(106.5-131.2)
Female	1	1.9	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	54	42.8	126.2	(94.8-164.7)					
Female	52	40.7	127.6	(95.3-167.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Mashpee

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	37	20.6	180.0	(126.7-248.1)	Male	16	11.7	136.2	(77.8-221.2)
Female	7	6.9	101.8	(40.8-209.7)	Female	11	8.7	126.6	(63.1-226.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	3.4	nc	(nc-nc)	Male	3	3.1	nc	(nc-nc)
Female	2	2.8	nc	(nc-nc)	Female	2	2.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.6	nc	(nc-nc)	Male	10	10.2	97.9	(46.9-180.1)
Female	82	63.3	129.5	(103.0-160.8)	Female	3	8.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	2.5	nc	(nc-nc)	Male	6	6.8	87.9	(32.1-191.3)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	37	26.2	141.2	(99.4-194.7)	Female	5	6.5	77.3	(24.9-180.4)
Female	15	23.0	65.3	(36.5-107.7)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	6	6.1	97.9	(35.7-213.0)
Male	9	5.1	178.0	(81.2-338.0)	Female	10	5.8	171.2	(81.9-314.8)
Female	3	1.3	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	92	73.1	125.9	(101.5-154.5)
Male	4	1.3	nc	(nc-nc)	<u>Stomach</u>				
Female	0	1.1	nc	(nc-nc)	Male	5	4.7	107.2	(34.6-250.3)
<u>Kidney & Renal Pelvis</u>					Female	1	2.5	nc	(nc-nc)
Male	14	9.2	152.6	(83.4-256.1)	<u>Testis</u>				
Female	7	5.4	130.0	(52.1-267.8)	Male	3	1.9	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	5	3.0	165.7	(53.4-386.7)	Male	3	2.9	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	6	9.4	64.1	(23.4-139.6)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	7	6.5	107.2	(42.9-220.8)	Female	17	14.4	118.2	(68.8-189.3)
Female	6	4.6	130.0	(47.5-283.0)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	335	258.0	129.9	(116.3-144.5)
Male	4	4.5	nc	(nc-nc)	Female	234	226.4	103.4	(90.6-117.5)
Female	2	1.5	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	44	37.3	118.1	(85.8-158.6)					
Female	39	33.9	115.1	(81.9-157.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Mattapoisett

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	7	9.1	77.3	(31.0-159.3)	Male	8	5.5	145.4	(62.6-286.5)
Female	1	3.2	nc	(nc-nc)	Female	4	4.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.6	nc	(nc-nc)	Male	4	1.4	nc	(nc-nc)
Female	2	1.3	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	2	4.7	nc	(nc-nc)
Female	21	31.1	67.6	(41.8-103.3)	Female	3	4.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.2	nc	(nc-nc)	Male	3	3.4	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	12	11.9	100.4	(51.8-175.4)	Female	5	3.1	159.6	(51.4-372.5)
Female	15	11.0	136.7	(76.4-225.4)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	4	2.8	nc	(nc-nc)
Male	1	2.4	nc	(nc-nc)	Female	1	2.7	nc	(nc-nc)
Female	2	0.6	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	28	34.9	80.2	(53.3-115.9)
Male	1	0.6	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.5	nc	(nc-nc)	Male	1	2.1	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	1.2	nc	(nc-nc)
Male	4	4.3	nc	(nc-nc)	<u>Testis</u>				
Female	3	2.6	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	1.4	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	7	4.4	159.6	(63.9-328.9)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	4	2.9	nc	(nc-nc)	Female	6	7.1	84.6	(30.9-184.2)
Female	2	2.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	106	119.3	88.9	(72.8-107.5)
Male	3	2.2	nc	(nc-nc)	Female	97	108.1	89.7	(72.7-109.4)
Female	0	0.7	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	12	16.7	72.0	(37.2-125.9)					
Female	14	15.7	89.3	(48.8-149.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Maynard

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	10	10.5	95.6	(45.8-175.9)	Male	10	6.9	145.3	(69.5-267.2)
Female	5	4.1	122.1	(39.3-284.8)	Female	8	5.9	136.3	(58.7-268.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	2.2	nc	(nc-nc)	Male	1	1.7	nc	(nc-nc)
Female	1	1.8	nc	(nc-nc)	Female	3	1.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.3	nc	(nc-nc)	Male	7	5.9	119.4	(47.8-246.0)
Female	39	41.2	94.6	(67.2-129.3)	Female	6	5.4	112.0	(40.9-243.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	1.8	nc	(nc-nc)	Male	3	4.2	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	10	14.2	70.6	(33.8-129.8)	Female	8	4.1	193.5	(83.3-381.3)
Female	10	14.3	69.8	(33.4-128.4)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	2	3.2	nc	(nc-nc)
Male	1	2.8	nc	(nc-nc)	Female	5	3.5	141.6	(45.6-330.4)
Female	0	0.8	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	32	39.0	82.0	(56.0-115.7)
Male	0	0.9	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.8	nc	(nc-nc)	Male	1	2.5	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	1.6	nc	(nc-nc)
Male	4	5.3	nc	(nc-nc)	<u>Testis</u>				
Female	3	3.3	nc	(nc-nc)	Male	0	1.6	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	1.6	nc	(nc-nc)	Male	4	2.0	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	6	6.7	89.1	(32.5-193.8)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	3.7	nc	(nc-nc)	Female	13	9.1	142.6	(75.9-243.9)
Female	4	2.9	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	127	140.8	90.2	(75.2-107.3)
Male	1	2.6	nc	(nc-nc)	Female	148	143.4	103.2	(87.3-121.3)
Female	2	1.0	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	17	19.0	89.6	(52.2-143.4)					
Female	14	19.8	70.6	(38.5-118.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Medfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	12	10.5	114.2	(58.9-199.5)	Male	15	7.5	199.0	(111.3-328.2)
Female	7	3.7	189.5	(75.9-390.4)	Female	8	6.0	132.7	(57.1-261.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	2.5	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)
Female	0	1.9	nc	(nc-nc)	Female	3	1.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	6	6.3	94.6	(34.5-205.9)
Female	60	43.6	137.5	(104.9-177.0)	Female	3	5.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.9	nc	(nc-nc)	Male	6	4.9	123.4	(45.1-268.7)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	22	14.9	147.8	(92.6-223.9)	Female	3	4.2	nc	(nc-nc)
Female	16	13.0	122.9	(70.2-199.6)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	7	3.4	208.7	(83.6-430.0)
Male	4	3.0	nc	(nc-nc)	Female	3	3.2	nc	(nc-nc)
Female	2	0.7	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	53	43.4	122.1	(91.4-159.6)
Male	2	1.0	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.8	nc	(nc-nc)	Male	0	2.5	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	1.4	nc	(nc-nc)
Male	3	5.9	nc	(nc-nc)	<u>Testis</u>				
Female	2	3.3	nc	(nc-nc)	Male	2	1.7	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	1.8	nc	(nc-nc)	Male	4	2.3	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	9	7.3	122.5	(55.9-232.5)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	4	4.0	nc	(nc-nc)	Female	12	9.5	126.6	(65.3-221.1)
Female	1	2.9	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	185	151.9	121.8	(104.9-140.7)
Male	2	3.1	nc	(nc-nc)	Female	162	142.3	113.9	(97.0-132.8)
Female	1	0.9	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	23	19.9	115.5	(73.2-173.3)					
Female	19	18.4	103.0	(62.0-160.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Medford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	75	68.8	109.1	(85.8-136.7)	Male	38	40.3	94.3	(66.7-129.5)
Female	41	27.7	148.2	(106.3-201.0)	Female	33	34.0	97.0	(66.7-136.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	7	12.0	58.6	(23.5-120.6)	Male	6	10.3	58.2	(21.2-126.7)
Female	15	10.7	140.7	(78.7-232.0)	Female	9	8.7	103.7	(47.3-196.8)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	2.0	nc	(nc-nc)	Male	30	35.1	85.5	(57.7-122.0)
Female	272	240.8	112.9	(99.9-127.2)	Female	32	34.7	92.2	(63.1-130.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	6	9.5	63.0	(23.0-137.2)	Male	22	23.0	95.7	(60.0-145.0)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	106	88.2	120.2	(98.4-145.4)	Female	19	25.1	75.7	(45.5-118.2)
Female	87	96.3	90.4	(72.4-111.5)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	21	20.4	102.7	(63.6-157.0)
Male	23	16.7	137.3	(87.0-206.1)	Female	18	24.1	74.8	(44.3-118.2)
Female	5	5.3	94.6	(30.5-220.8)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	184	236.9	77.7	(66.9-89.7)
Male	8	5.4	149.3	(64.3-294.2)	<u>Stomach</u>				
Female	7	4.4	157.6	(63.1-324.7)	Male	12	15.8	76.0	(39.2-132.8)
<u>Kidney & Renal Pelvis</u>					Female	11	10.8	101.7	(50.7-181.9)
Male	32	30.9	103.5	(70.7-146.1)	<u>Testis</u>				
Female	18	20.7	86.9	(51.5-137.3)	Male	6	8.6	69.6	(25.4-151.5)
<u>Larynx</u>					<u>Thyroid</u>				
Male	12	9.9	121.1	(62.5-211.6)	Male	13	10.4	124.5	(66.3-213.0)
Female	3	3.0	nc	(nc-nc)	Female	46	35.1	131.1	(96.0-174.9)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	19	22.5	84.6	(50.9-132.1)	Female	55	53.5	102.8	(77.5-133.9)
Female	22	18.7	117.9	(73.9-178.6)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	844	862.8	97.8	(91.3-104.7)
Male	18	15.0	120.0	(71.1-189.7)	Female	921	886.8	103.9	(97.3-110.8)
Female	13	6.2	210.0	(111.7-359.1)					
<u>Lung and Bronchus</u>									
Male	127	122.9	103.3	(86.1-122.9)					
Female	133	130.7	101.8	(85.2-120.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Medway

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	7	9.9	70.4	(28.2-145.1)	Male	6	7.2	83.7	(30.6-182.1)
Female	7	3.9	181.8	(72.8-374.6)	Female	8	6.2	128.9	(55.5-254.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	2.4	nc	(nc-nc)	Male	2	1.6	nc	(nc-nc)
Female	0	2.0	nc	(nc-nc)	Female	2	1.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	13	6.1	214.5	(114.1-366.7)
Female	34	42.9	79.3	(54.9-110.8)	Female	10	5.2	192.2	(92.0-353.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	2.0	nc	(nc-nc)	Male	5	4.5	112.3	(36.2-262.0)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	10	14.0	71.3	(34.1-131.2)	Female	2	4.2	nc	(nc-nc)
Female	20	13.7	146.3	(89.3-225.9)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	3	2.8	nc	(nc-nc)	Male	7	3.1	222.9	(89.3-459.3)
Female	0	0.7	nc	(nc-nc)	Female	3	3.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Stomach</u>				
Male	3	1.1	nc	(nc-nc)	Male	1	2.4	nc	(nc-nc)
Female	2	0.9	nc	(nc-nc)	Female	1	1.5	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					<u>Testis</u>				
Male	4	5.6	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
Female	1	3.3	nc	(nc-nc)	<u>Thyroid</u>				
<u>Larynx</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	1.7	nc	(nc-nc)	Female	10	9.1	109.8	(52.6-202.0)
Female	0	0.5	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	5	3.8	130.4	(42.0-304.2)	Male	152	142.2	106.9	(90.6-125.3)
Female	3	3.1	nc	(nc-nc)	Female	141	144.0	97.9	(82.4-115.5)
<u>Liver and Intrahepatic Bile Ducts</u>									
Male	0	2.8	nc	(nc-nc)					
Female	0	0.9	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	13	18.6	70.0	(37.2-119.8)					
Female	18	18.7	96.3	(57.1-152.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Melrose

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	32	33.1	96.6	(66.1-136.4)	Male	25	20.1	124.5	(80.5-183.8)
Female	17	13.4	127.1	(74.0-203.5)	Female	29	16.8	172.6	(115.6-247.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	7	6.0	116.5	(46.7-240.0)	Male	4	5.1	nc	(nc-nc)
Female	6	5.3	114.2	(41.7-248.6)	Female	4	4.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.0	nc	(nc-nc)	Male	22	17.4	126.7	(79.4-191.9)
Female	114	120.7	94.4	(77.9-113.4)	Female	18	16.9	106.7	(63.2-168.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	4.8	nc	(nc-nc)	Male	8	11.9	67.4	(29.0-132.9)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	36	43.6	82.6	(57.9-114.4)	Female	8	12.4	64.4	(27.7-126.8)
Female	56	47.2	118.7	(89.7-154.2)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	9	10.0	90.3	(41.2-171.4)
Male	2	8.3	nc	(nc-nc)	Female	11	11.7	94.2	(46.9-168.5)
Female	5	2.6	196.0	(63.2-457.5)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	117	117.2	99.8	(82.5-119.6)
Male	3	2.5	nc	(nc-nc)	<u>Stomach</u>				
Female	4	2.0	nc	(nc-nc)	Male	9	7.7	116.9	(53.4-222.0)
<u>Kidney & Renal Pelvis</u>					Female	2	5.3	nc	(nc-nc)
Male	24	15.5	154.9	(99.2-230.5)	<u>Testis</u>				
Female	11	10.2	108.2	(53.9-193.5)	Male	2	4.0	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	4	4.9	nc	(nc-nc)	Male	5	5.3	93.7	(30.2-218.6)
Female	0	1.5	nc	(nc-nc)	Female	17	17.6	96.8	(56.4-155.0)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	11	11.1	99.5	(49.6-178.0)	Female	26	26.6	97.6	(63.8-143.1)
Female	5	9.2	54.6	(17.6-127.3)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	413	424.3	97.3	(88.2-107.2)
Male	5	7.7	64.9	(20.9-151.4)	Female	447	436.7	102.3	(93.1-112.3)
Female	3	3.0	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	61	59.1	103.2	(79.0-132.6)					
Female	72	62.9	114.5	(89.6-144.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Mendon

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	4.6	108.6	(35.0-253.5)	Male	5	3.4	145.7	(46.9-339.9)
Female	0	1.6	nc	(nc-nc)	Female	2	2.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.1	nc	(nc-nc)	Male	2	0.8	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	2	0.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	2.9	nc	(nc-nc)
Female	18	19.1	94.4	(55.9-149.3)	Female	2	2.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.9	nc	(nc-nc)	Male	1	2.2	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	7	6.6	105.3	(42.2-217.0)	Female	3	1.8	nc	(nc-nc)
Female	9	5.6	161.3	(73.6-306.3)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	0	1.3	nc	(nc-nc)	Male	0	1.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	4	1.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.5	nc	(nc-nc)	Male	29	18.9	153.4	(102.7-220.3)
Female	1	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	2	2.6	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	2	1.4	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	0	0.8	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	0	1.8	nc	(nc-nc)	Male	3	1.1	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)	Female	2	3.5	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	1.4	nc	(nc-nc)	Female	1	4.1	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	10	8.6	116.4	(55.7-214.1)	Male	76	67.3	112.9	(89.0-141.3)
Female	5	7.7	64.6	(20.8-150.8)	Female	58	61.9	93.7	(71.1-121.1)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Merrimac

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	7	6.4	110.2	(44.2-227.1)	Male	4	4.2	nc	(nc-nc)
Female	5	2.1	239.9	(77.3-559.8)	Female	3	3.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.3	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	3	3.6	nc	(nc-nc)
Female	30	23.4	128.4	(86.6-183.3)	Female	4	2.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.0	nc	(nc-nc)	Male	3	2.6	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	7	8.6	80.9	(32.4-166.8)	Female	5	2.3	219.4	(70.7-511.9)
Female	11	7.1	154.0	(76.7-275.5)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	1	2.0	nc	(nc-nc)
Male	1	1.7	nc	(nc-nc)	Female	1	1.8	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	28	24.3	115.5	(76.7-166.9)
Male	0	0.6	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.4	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	2	0.8	nc	(nc-nc)
Male	3	3.2	nc	(nc-nc)	<u>Testis</u>				
Female	3	1.8	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	1.0	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	4.0	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	5	2.3	220.6	(71.1-514.7)	Female	9	5.2	174.1	(79.4-330.5)
Female	3	1.6	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	89	86.2	103.2	(82.9-127.0)
Male	1	1.6	nc	(nc-nc)	Female	98	77.8	126.0	(102.3-153.6)
Female	0	0.5	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	10	11.6	86.2	(41.3-158.5)					
Female	16	10.5	152.1	(86.9-247.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Methuen

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	60	50.5	118.9	(90.7-153.0)	Male	25	30.8	81.2	(52.5-119.9)
Female	18	20.2	89.3	(52.9-141.1)	Female	19	25.9	73.4	(44.2-114.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	10	9.5	104.8	(50.2-192.7)	Male	9	7.7	116.5	(53.2-221.2)
Female	10	8.2	121.3	(58.1-223.0)	Female	9	6.4	141.4	(64.5-268.4)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.5	nc	(nc-nc)	Male	21	26.8	78.3	(48.4-119.7)
Female	169	182.9	92.4	(79.0-107.4)	Female	18	25.6	70.2	(41.6-111.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	7.5	nc	(nc-nc)	Male	16	18.0	88.8	(50.7-144.2)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	72	66.1	108.9	(85.2-137.2)	Female	16	18.8	85.0	(48.6-138.0)
Female	67	70.7	94.8	(73.5-120.4)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	19	15.2	125.1	(75.3-195.4)
Male	9	12.6	71.3	(32.5-135.3)	Female	19	17.6	108.2	(65.1-169.0)
Female	5	3.8	129.9	(41.9-303.1)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	168	176.6	95.2	(81.3-110.7)
Male	3	4.2	nc	(nc-nc)	<u>Stomach</u>				
Female	3	3.4	nc	(nc-nc)	Male	12	11.7	102.4	(52.9-178.9)
<u>Kidney & Renal Pelvis</u>					Female	5	7.9	63.1	(20.3-147.3)
Male	27	23.7	113.7	(74.9-165.4)	<u>Testis</u>				
Female	15	15.5	97.1	(54.3-160.1)	Male	13	6.7	193.5	(102.9-330.9)
<u>Larynx</u>					<u>Thyroid</u>				
Male	13	7.5	174.5	(92.8-298.4)	Male	7	8.3	83.9	(33.6-173.0)
Female	2	2.2	nc	(nc-nc)	Female	32	27.5	116.3	(79.5-164.2)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	14	17.2	81.3	(44.4-136.5)	Female	46	40.1	114.8	(84.1-153.2)
Female	10	14.1	71.1	(34.0-130.7)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	650	647.6	100.4	(92.8-108.4)
Male	15	11.7	128.5	(71.9-211.9)	Female	650	662.5	98.1	(90.7-105.9)
Female	1	4.6	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	79	90.4	87.4	(69.2-108.9)					
Female	97	95.4	101.7	(82.5-124.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Middleborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	29	19.0	152.8	(102.3-219.5)	Male	24	12.9	185.4	(118.8-275.9)
Female	13	7.2	179.8	(95.6-307.5)	Female	11	10.8	101.6	(50.6-181.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	4.2	119.0	(38.3-277.6)	Male	1	3.1	nc	(nc-nc)
Female	6	3.4	177.2	(64.7-385.8)	Female	4	2.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.6	nc	(nc-nc)	Male	18	11.0	163.1	(96.6-257.8)
Female	59	74.7	79.0	(60.1-101.9)	Female	12	9.6	124.8	(64.4-218.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	3.4	nc	(nc-nc)	Male	8	8.0	100.2	(43.1-197.4)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	36	26.2	137.4	(96.2-190.2)	Female	11	7.5	146.8	(73.2-262.7)
Female	26	25.6	101.7	(66.4-149.0)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	5	5.9	84.3	(27.2-196.8)
Male	9	5.2	174.1	(79.4-330.4)	Female	6	6.3	95.9	(35.0-208.8)
Female	3	1.4	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	82	73.2	112.0	(89.1-139.1)
Male	2	2.0	nc	(nc-nc)	<u>Stomach</u>				
Female	1	1.5	nc	(nc-nc)	Male	4	4.5	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	2	2.8	nc	(nc-nc)
Male	13	10.0	130.2	(69.3-222.7)	<u>Testis</u>				
Female	11	5.9	185.1	(92.3-331.3)	Male	4	3.3	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	4	3.1	nc	(nc-nc)	Male	4	3.9	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	16	12.6	126.5	(72.3-205.5)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	9	7.0	129.3	(59.0-245.4)	Female	16	16.4	97.8	(55.8-158.8)
Female	4	5.4	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	346	262.7	131.7	(118.2-146.3)
Male	5	5.0	99.0	(31.9-231.1)	Female	269	258.3	104.2	(92.1-117.4)
Female	0	1.7	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	57	34.8	163.7	(124.0-212.1)					
Female	39	34.8	112.0	(79.6-153.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Middlefield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.6	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	3	2.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	0	0.8	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	2	0.6	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	1	2.4	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.1	nc	(nc-nc)
Male	1	0.3	nc	(nc-nc)	<u>Testis</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	0.2	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	6	8.4	71.3	(26.0-155.3)
Male	0	0.2	nc	(nc-nc)	Female	5	6.7	75.0	(24.2-175.1)
Female	0	0.0	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	1	1.1	nc	(nc-nc)					
Female	0	0.9	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Middleton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	7	8.1	86.1	(34.5-177.5)	Male	7	6.0	117.5	(47.1-242.2)
Female	2	2.6	nc	(nc-nc)	Female	5	3.9	126.9	(40.9-296.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	2.0	nc	(nc-nc)	Male	4	1.3	nc	(nc-nc)
Female	2	1.2	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	5	5.0	99.9	(32.2-233.1)
Female	32	28.5	112.3	(76.8-158.5)	Female	8	3.5	228.5	(98.4-450.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.2	nc	(nc-nc)	Male	1	3.6	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	7	11.3	61.7	(24.7-127.2)	Female	2	2.8	nc	(nc-nc)
Female	4	9.0	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	2	2.5	nc	(nc-nc)
Male	2	2.2	nc	(nc-nc)	Female	1	2.2	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	35	31.6	110.8	(77.2-154.1)
Male	2	1.1	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.5	nc	(nc-nc)	Male	0	2.0	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	1.0	nc	(nc-nc)
Male	1	4.4	nc	(nc-nc)	<u>Testis</u>				
Female	2	2.3	nc	(nc-nc)	Male	0	2.0	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	1.3	nc	(nc-nc)	Male	0	1.9	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	3	4.6	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	3	3.1	nc	(nc-nc)	Female	6	6.4	93.3	(34.1-203.1)
Female	3	1.9	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	115	115.8	99.3	(82.0-119.2)
Male	4	2.2	nc	(nc-nc)	Female	103	95.9	107.4	(87.6-130.2)
Female	0	0.6	nc	(nc-nc)	<u>Lung and Bronchus</u>				
Male	16	15.0	106.6	(60.9-173.2)	<u>Bladder, Urinary</u>				
Female	23	13.3	173.2	(109.8-259.9)	Male	7	8.1	86.1	(34.5-177.5)
					Female	2	2.6	nc	(nc-nc)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Milford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	38	27.1	140.4	(99.4-192.8)	Male	11	17.7	62.0	(30.9-110.9)
Female	8	10.9	73.7	(31.7-145.1)	Female	13	15.2	85.5	(45.5-146.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	5.7	106.1	(38.7-231.0)	Male	3	4.3	nc	(nc-nc)
Female	9	4.7	189.7	(86.6-360.1)	Female	5	3.5	144.7	(46.6-337.8)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.8	nc	(nc-nc)	Male	9	15.2	59.2	(27.0-112.3)
Female	96	104.9	91.5	(74.1-111.8)	Female	15	14.2	106.0	(59.3-174.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	7	4.6	153.1	(61.3-315.5)	Male	6	10.7	56.0	(20.4-121.8)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	42	36.6	114.8	(82.7-155.1)	Female	7	10.7	65.5	(26.2-135.0)
Female	38	38.7	98.2	(69.4-134.7)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	4	8.3	nc	(nc-nc)
Male	10	7.1	140.0	(67.0-257.5)	Female	10	9.5	105.7	(50.6-194.4)
Female	2	2.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	109	100.5	108.4	(89.0-130.8)
Male	0	2.6	nc	(nc-nc)	<u>Stomach</u>				
Female	2	2.0	nc	(nc-nc)	Male	10	6.4	156.8	(75.1-288.5)
<u>Kidney & Renal Pelvis</u>					Female	4	4.3	nc	(nc-nc)
Male	16	13.7	116.9	(66.7-189.8)	<u>Testis</u>				
Female	7	8.6	81.8	(32.8-168.6)	Male	3	4.4	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	4.2	nc	(nc-nc)	Male	4	5.1	nc	(nc-nc)
Female	2	1.2	nc	(nc-nc)	Female	17	17.0	99.9	(58.2-160.0)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	10	9.6	103.9	(49.7-191.0)	Female	17	23.0	73.9	(43.0-118.4)
Female	9	7.9	114.0	(52.0-216.5)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	371	364.2	101.9	(91.8-112.8)
Male	8	6.9	116.7	(50.2-229.9)	Female	349	372.3	93.7	(84.2-104.1)
Female	1	2.5	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	54	49.3	109.6	(82.3-143.0)					
Female	53	51.2	103.6	(77.6-135.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Millbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	17	15.8	107.7	(62.7-172.5)	Male	9	9.8	91.6	(41.8-173.8)
Female	8	6.3	126.5	(54.5-249.3)	Female	3	8.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	3.0	nc	(nc-nc)	Male	2	2.4	nc	(nc-nc)
Female	1	2.5	nc	(nc-nc)	Female	2	2.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	10	8.5	118.3	(56.7-217.6)
Female	64	57.7	110.9	(85.4-141.6)	Female	6	8.0	75.1	(27.4-163.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	2.3	nc	(nc-nc)	Male	9	5.9	152.4	(69.5-289.3)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	22	21.0	104.9	(65.7-158.8)	Female	4	5.9	nc	(nc-nc)
Female	19	22.2	85.6	(51.5-133.7)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	2	4.1	nc	(nc-nc)	Male	55	58.0	94.9	(71.5-123.5)
Female	1	1.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	2	1.3	nc	(nc-nc)	Male	2	2.0	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	9	7.6	118.6	(54.1-225.2)	Female	16	12.8	124.5	(71.1-202.3)
Female	5	4.8	103.7	(33.4-241.9)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	3	2.4	nc	(nc-nc)	Male	212	206.8	102.5	(89.2-117.3)
Female	1	0.7	nc	(nc-nc)	Female	217	208.0	104.3	(90.9-119.2)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	4	5.3	nc	(nc-nc)	<u>All Sites / Types</u>				
Female	4	4.4	nc	(nc-nc)	Male	212	206.8	102.5	(89.2-117.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	3	3.8	nc	(nc-nc)	Female	217	208.0	104.3	(90.9-119.2)
Female	0	1.4	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	34	28.4	119.5	(82.8-167.1)	Male	212	206.8	102.5	(89.2-117.3)
Female	43	29.8	144.3	(104.5-194.4)	Female	217	208.0	104.3	(90.9-119.2)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Millis

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	7	6.6	105.3	(42.2-217.0)	Male	6	4.8	124.4	(45.4-270.7)
Female	3	2.4	nc	(nc-nc)	Female	8	4.1	195.2	(84.0-384.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.6	nc	(nc-nc)	Male	3	1.1	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)	Female	2	0.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.2	nc	(nc-nc)	Male	4	4.0	nc	(nc-nc)
Female	33	29.0	113.7	(78.3-159.7)	Female	3	3.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.3	nc	(nc-nc)	Male	4	3.1	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	10	9.5	105.7	(50.6-194.4)	Female	4	2.8	nc	(nc-nc)
Female	6	8.4	71.5	(26.1-155.6)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	2	2.1	nc	(nc-nc)
Male	3	1.9	nc	(nc-nc)	Female	0	2.1	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	30	28.1	106.9	(72.1-152.7)
Male	1	0.7	nc	(nc-nc)	<u>Stomach</u>				
Female	1	0.6	nc	(nc-nc)	Male	3	1.6	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	0.9	nc	(nc-nc)
Male	3	3.8	nc	(nc-nc)	<u>Testis</u>				
Female	1	2.2	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	1.2	nc	(nc-nc)	Male	4	1.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	6	5.1	117.6	(42.9-256.0)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	5	2.5	199.1	(64.2-464.7)	Female	3	6.4	nc	(nc-nc)
Female	6	1.9	320.5	(117.0-697.5)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	112	97.2	115.2	(94.9-138.6)
Male	1	2.0	nc	(nc-nc)	Female	105	94.6	111.0	(90.8-134.4)
Female	1	0.6	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	13	12.7	102.5	(54.5-175.3)					
Female	14	12.4	112.8	(61.6-189.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Millville

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	1.9	nc	(nc-nc)	Male	0	1.5	nc	(nc-nc)
Female	2	0.7	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.5	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	1.2	nc	(nc-nc)
Female	8	8.5	94.4	(40.6-186.0)	Female	0	1.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.4	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	3	2.7	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
Female	1	2.6	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	0	0.5	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Female	1	0.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male				
Male	0	0.3	nc	(nc-nc)	Female	9	7.7	116.8	(53.3-221.8)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	1	1.1	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male				
Male	0	0.3	nc	(nc-nc)	Female	2	1.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	0	0.8	nc	(nc-nc)	Female	2	1.7	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Female				
Male	0	0.5	nc	(nc-nc)	Male	27	28.1	96.1	(63.3-139.8)
Female	0	0.2	nc	(nc-nc)	Female	27	28.5	94.6	(62.3-137.6)
<u>Lung and Bronchus</u>					<u>All Sites / Types</u>				
Male	3	3.6	nc	(nc-nc)					
Female	6	3.7	162.6	(59.4-354.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Milton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	30	30.8	97.3	(65.6-138.9)	Male	34	18.6	183.0	(126.7-255.7)
Female	12	12.3	97.5	(50.3-170.3)	Female	31	15.6	198.1	(134.6-281.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	5.7	nc	(nc-nc)	Male	6	4.7	127.0	(46.4-276.5)
Female	4	5.0	nc	(nc-nc)	Female	10	3.9	257.2	(123.1-473.0)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.9	nc	(nc-nc)	Male	18	16.2	111.1	(65.8-175.6)
Female	136	113.0	120.4	(101.0-142.4)	Female	24	15.6	153.9	(98.5-228.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	4.4	nc	(nc-nc)	Male	13	11.0	118.1	(62.8-202.0)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	47	40.5	116.0	(85.2-154.2)	Female	16	11.6	138.2	(79.0-224.5)
Female	35	43.7	80.1	(55.8-111.5)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	6	9.3	64.7	(23.6-140.8)
Male	4	7.7	nc	(nc-nc)	Female	5	10.8	46.4	(14.9-108.2)
Female	3	2.3	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	114	107.8	105.7	(87.2-127.0)
Male	2	2.3	nc	(nc-nc)	<u>Stomach</u>				
Female	2	1.9	nc	(nc-nc)	Male	6	7.2	83.8	(30.6-182.3)
<u>Kidney & Renal Pelvis</u>					Female	4	4.9	nc	(nc-nc)
Male	14	14.4	97.1	(53.0-162.9)	<u>Testis</u>				
Female	14	9.4	149.3	(81.5-250.4)	Male	5	3.5	142.9	(46.0-333.4)
<u>Larynx</u>					<u>Thyroid</u>				
Male	4	4.5	nc	(nc-nc)	Male	10	4.9	203.0	(97.2-373.4)
Female	1	1.4	nc	(nc-nc)	Female	17	16.4	104.0	(60.5-166.5)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	9	10.4	86.2	(39.3-163.6)	Female	30	24.5	122.3	(82.5-174.7)
Female	9	8.6	105.1	(47.9-199.5)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	396	393.7	100.6	(90.9-111.0)
Male	12	7.2	167.4	(86.4-292.5)	Female	458	405.3	113.0	(102.9-123.8)
Female	3	2.8	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	34	55.0	61.8	(42.8-86.4)					
Female	61	57.7	105.7	(80.8-135.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Monroe

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	0	0.1	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	0	0.0	nc	(nc-nc)
Male	0	0.0	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	3	0.4	nc	(nc-nc)
Male	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.0	nc	(nc-nc)
Male	0	0.0	nc	(nc-nc)	<u>Testis</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.0	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	4	1.2	nc	(nc-nc)
Male	0	0.0	nc	(nc-nc)	Female	0	1.7	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Lung and Bronchus</u>				
Male	1	0.1	nc	(nc-nc)					
Female	0	0.2	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Monson

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	8.4	nc	(nc-nc)	Male	10	5.8	171.9	(82.3-316.1)
Female	5	3.0	164.6	(53.0-384.1)	Female	6	4.6	129.8	(47.4-282.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.8	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	0	1.4	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	3	4.9	nc	(nc-nc)
Female	25	32.8	76.2	(49.3-112.6)	Female	6	4.1	147.3	(53.8-320.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	1.4	nc	(nc-nc)	Male	8	3.7	217.0	(93.4-427.6)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	12	11.7	102.7	(53.0-179.4)	Female	4	3.2	nc	(nc-nc)
Female	8	10.6	75.2	(32.4-148.2)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	4	2.7	nc	(nc-nc)
Male	0	2.4	nc	(nc-nc)	Female	7	2.6	267.9	(107.3-551.9)
Female	1	0.6	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	35	33.7	103.8	(72.3-144.3)
Male	3	0.8	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.6	nc	(nc-nc)	Male	2	2.0	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	1.2	nc	(nc-nc)
Male	2	4.6	nc	(nc-nc)	<u>Testis</u>				
Female	2	2.6	nc	(nc-nc)	Male	2	1.4	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	1.4	nc	(nc-nc)	Male	0	1.7	nc	(nc-nc)
Female	2	0.4	nc	(nc-nc)	Female	1	5.4	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	3.0	nc	(nc-nc)	Female	4	7.3	nc	(nc-nc)
Female	2	2.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	115	118.4	97.1	(80.2-116.6)
Male	0	2.3	nc	(nc-nc)	Female	99	110.9	89.3	(72.5-108.7)
Female	0	0.7	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	19	15.7	121.0	(72.8-189.0)					
Female	14	15.0	93.6	(51.1-157.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Montague

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	10.1	nc	(nc-nc)	Male	2	6.2	nc	(nc-nc)
Female	3	4.0	nc	(nc-nc)	Female	2	5.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	1.9	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
Female	1	1.6	nc	(nc-nc)	Female	3	1.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	2	5.4	nc	(nc-nc)
Female	34	36.5	93.1	(64.5-130.2)	Female	4	5.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.4	nc	(nc-nc)	Male	4	3.7	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	13	13.4	97.3	(51.8-166.4)	Female	6	3.8	159.3	(58.2-346.7)
Female	12	13.8	86.9	(44.9-151.9)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	5	3.1	162.7	(52.4-379.7)
Male	3	2.6	nc	(nc-nc)	Female	3	3.5	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	26	36.5	71.2	(46.5-104.4)
Male	2	0.8	nc	(nc-nc)	<u>Stomach</u>				
Female	2	0.7	nc	(nc-nc)	Male	4	2.3	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	1.5	nc	(nc-nc)
Male	4	4.8	nc	(nc-nc)	<u>Testis</u>				
Female	2	3.1	nc	(nc-nc)	Male	2	1.3	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	1.5	nc	(nc-nc)	Male	2	1.7	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	2	5.4	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	5	3.4	147.6	(47.6-344.4)	Female	9	8.2	109.7	(50.0-208.2)
Female	3	2.7	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	106	131.3	80.7	(66.1-97.6)
Male	0	2.4	nc	(nc-nc)	Female	116	131.6	88.2	(72.9-105.8)
Female	0	0.9	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	19	18.3	103.9	(62.5-162.2)					
Female	20	19.3	103.8	(63.4-160.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Monterey

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	1.4	nc	(nc-nc)	Male	3	0.9	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	1	0.2	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	7	4.4	159.2	(63.8-328.1)	Female	0	0.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	2	1.9	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Female	0	1.3	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	1	0.4	nc	(nc-nc)
Male	1	0.4	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	7	5.7	122.5	(49.1-252.3)
Male	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.1	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	<u>Testis</u>				
Female	0	0.3	nc	(nc-nc)	Male	1	0.1	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.4	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	24	19.1	125.5	(80.4-186.7)
Male	0	0.4	nc	(nc-nc)	Female	10	14.5	69.0	(33.0-127.0)
Female	0	0.1	nc	(nc-nc)	<u>Lung and Bronchus</u>				
Male	5	2.7	186.2	(60.0-434.5)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	2.1	nc	(nc-nc)	<u>All Sites / Types</u>				

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Montgomery

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	0.8	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	2	3.0	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	0	1.2	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	0	0.3	nc	(nc-nc)
Male	1	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	0	3.6	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.1	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	<u>Testis</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.3	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	8	12.0	66.5	(28.6-131.1)
Male	0	0.2	nc	(nc-nc)	Female	5	9.6	52.1	(16.8-121.5)
Female	0	0.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	4	1.6	nc	(nc-nc)					
Female	1	1.3	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Mount Washington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	0	0.4	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male				
Male	0	0.0	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male				
Male	0	0.0	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	1	0.1	nc	(nc-nc)	Female	1	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Female				
Male	0	0.1	nc	(nc-nc)	Male	2	3.4	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	4	2.5	nc	(nc-nc)
<u>Lung and Bronchus</u>					<u>All Sites / Types</u>				
Male	1	0.5	nc	(nc-nc)					
Female	0	0.4	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Nahant

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	8	6.0	132.6	(57.1-261.3)	Male	4	3.5	nc	(nc-nc)
Female	1	2.0	nc	(nc-nc)	Female	3	2.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.0	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	2	3.0	nc	(nc-nc)
Female	16	18.4	86.9	(49.6-141.1)	Female	1	2.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.7	nc	(nc-nc)	Male	5	2.1	243.1	(78.3-567.3)
<u>Colon / Rectum</u>					Female	1	0.9	nc	(nc-nc)
Male	9	7.8	115.2	(52.6-218.7)	<u>Ovary</u>				
Female	6	7.0	85.5	(31.2-186.1)	Female	3	1.9	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	1.5	nc	(nc-nc)	Male	3	1.8	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	1.7	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.3	nc	(nc-nc)	Male	19	20.8	91.5	(55.1-142.9)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	1.4	nc	(nc-nc)
Male	0	2.7	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
Female	0	1.5	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	0.5	nc	(nc-nc)
Male	1	0.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
<u>Leukemia</u>					Female	2	2.5	nc	(nc-nc)
Male	5	1.9	261.5	(84.3-610.2)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	1.3	nc	(nc-nc)	Female	2	4.1	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	1.3	nc	(nc-nc)	Male	79	74.9	105.5	(83.5-131.5)
Female	1	0.5	nc	(nc-nc)	Female	56	65.4	85.6	(64.7-111.2)
<u>Lung and Bronchus</u>									
Male	10	10.6	94.1	(45.1-173.1)					
Female	15	9.4	159.7	(89.3-263.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Nantucket

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	12	8.7	138.0	(71.2-241.1)	Male	14	6.2	224.8	(122.8-377.2)
Female	7	3.2	218.3	(87.5-449.8)	Female	7	5.0	138.9	(55.7-286.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	2.0	nc	(nc-nc)	Male	0	1.4	nc	(nc-nc)
Female	0	1.5	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	8	5.2	153.4	(66.0-302.2)
Female	41	33.3	123.0	(88.3-166.9)	Female	2	4.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	1.6	nc	(nc-nc)	Male	2	3.7	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	16	12.0	132.9	(75.9-215.9)	Female	8	3.3	240.8	(103.7-474.5)
Female	23	11.0	208.3	(132.0-312.5)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	4	2.7	nc	(nc-nc)
Male	2	2.4	nc	(nc-nc)	Female	2	2.7	nc	(nc-nc)
Female	2	0.6	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	79	33.8	233.4	(184.8-290.9)
Male	2	1.1	nc	(nc-nc)	<u>Stomach</u>				
Female	2	0.8	nc	(nc-nc)	Male	1	2.1	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	1.2	nc	(nc-nc)
Male	1	4.7	nc	(nc-nc)	<u>Testis</u>				
Female	3	2.7	nc	(nc-nc)	Male	2	2.0	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	1.4	nc	(nc-nc)	Male	2	2.0	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	1	6.2	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	3.2	nc	(nc-nc)	Female	5	7.2	69.5	(22.4-162.1)
Female	3	2.4	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	173	122.8	140.9	(120.7-163.5)
Male	1	2.3	nc	(nc-nc)	Female	140	115.5	121.2	(101.9-143.0)
Female	1	0.7	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	13	16.3	79.9	(42.5-136.7)					
Female	12	15.7	76.5	(39.5-133.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Natick

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	31	35.9	86.5	(58.7-122.7)	Male	30	22.6	132.7	(89.5-189.4)
Female	21	14.2	147.6	(91.3-225.6)	Female	14	19.2	72.9	(39.8-122.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	14	7.0	200.9	(109.7-337.0)	Male	6	5.6	107.5	(39.2-233.9)
Female	5	6.0	83.5	(26.9-194.9)	Female	4	4.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.1	nc	(nc-nc)	Male	15	19.3	77.6	(43.4-128.1)
Female	133	136.2	97.7	(81.8-115.7)	Female	17	18.2	93.2	(54.2-149.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	5.7	nc	(nc-nc)	Male	10	13.5	74.1	(35.5-136.3)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	47	47.6	98.8	(72.6-131.4)	Female	12	13.8	87.0	(44.9-152.0)
Female	56	49.5	113.0	(85.4-146.8)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	10	10.9	91.4	(43.8-168.2)
Male	7	9.3	75.3	(30.2-155.2)	Female	16	12.3	130.2	(74.4-211.5)
Female	1	2.7	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	140	133.2	105.1	(88.4-124.0)
Male	2	2.9	nc	(nc-nc)	<u>Stomach</u>				
Female	0	2.4	nc	(nc-nc)	Male	5	8.3	59.9	(19.3-139.9)
<u>Kidney & Renal Pelvis</u>					Female	8	5.5	144.7	(62.3-285.1)
Male	19	17.5	108.3	(65.2-169.1)	<u>Testis</u>				
Female	9	11.2	80.1	(36.6-152.1)	Male	6	4.9	121.6	(44.4-264.7)
<u>Larynx</u>					<u>Thyroid</u>				
Male	9	5.6	162.0	(73.9-307.5)	Male	6	6.3	95.4	(34.8-207.7)
Female	1	1.7	nc	(nc-nc)	Female	26	21.2	122.6	(80.0-179.6)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	10	12.2	81.7	(39.1-150.3)	Female	23	30.1	76.4	(48.4-114.7)
Female	13	10.0	129.8	(69.1-222.0)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	454	474.0	95.8	(87.2-105.0)
Male	4	8.7	nc	(nc-nc)	Female	478	481.8	99.2	(90.5-108.5)
Female	1	3.3	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	56	65.6	85.4	(64.5-110.8)					
Female	64	68.4	93.6	(72.1-119.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Needham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	41	38.0	107.9	(77.4-146.3)	Male	30	22.3	134.6	(90.8-192.2)
Female	11	15.3	71.7	(35.7-128.2)	Female	27	18.3	147.5	(97.2-214.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	8	6.7	120.1	(51.7-236.6)	Male	6	5.8	104.1	(38.0-226.5)
Female	5	5.8	86.4	(27.8-201.7)	Female	6	4.8	124.7	(45.5-271.4)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.1	nc	(nc-nc)	Male	21	19.5	107.8	(66.7-164.8)
Female	166	133.8	124.1	(105.9-144.4)	Female	34	19.2	177.5	(122.9-248.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	5	5.1	98.9	(31.9-230.9)	Male	11	13.1	83.7	(41.7-149.8)
Female					Female	8	6.9	115.7	(49.8-227.9)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	45	49.5	90.8	(66.2-121.5)	Female	10	13.9	71.9	(34.4-132.3)
Female	57	55.1	103.4	(78.3-133.9)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	12	11.4	105.4	(54.4-184.1)
Male	6	9.4	64.1	(23.4-139.5)	Female	14	13.5	103.5	(56.5-173.7)
Female	1	2.9	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	145	131.5	110.3	(93.0-129.7)
Male	4	2.5	nc	(nc-nc)	<u>Stomach</u>				
Female	3	2.0	nc	(nc-nc)	Male	4	8.8	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	3	6.3	nc	(nc-nc)
Male	16	17.4	92.2	(52.6-149.7)	<u>Testis</u>				
Female	8	11.2	71.2	(30.7-140.3)	Male	5	3.6	137.0	(44.2-319.8)
<u>Larynx</u>					<u>Thyroid</u>				
Male	4	5.5	nc	(nc-nc)	Male	14	5.7	246.7	(134.8-414.0)
Female	2	1.6	nc	(nc-nc)	Female	23	18.1	127.0	(80.5-190.5)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	14	12.6	111.2	(60.7-186.5)	Female	27	29.3	92.1	(60.7-134.0)
Female	10	10.5	95.0	(45.5-174.7)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	470	477.9	98.3	(89.6-107.6)
Male	6	8.6	70.0	(25.5-152.3)	Female	519	489.6	106.0	(97.1-115.5)
Female	1	3.5	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	43	67.3	63.9	(46.2-86.0)					
Female	59	70.1	84.2	(64.1-108.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

New Ashford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.1	nc	(nc-nc)
Female	3	0.9	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	0	0.3	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male				
Male	0	0.0	nc	(nc-nc)	Female	4	0.9	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	0	0.1	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male				
Male	0	0.0	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	0	0.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Female				
Male	0	0.1	nc	(nc-nc)	Male	6	3.3	179.7	(65.6-391.1)
Female	0	0.0	nc	(nc-nc)	Female	4	3.0	nc	(nc-nc)
<u>Lung and Bronchus</u>					<u>All Sites / Types</u>				
Male	0	0.5	nc	(nc-nc)					
Female	0	0.4	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

New Bedford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	112	106.1	105.6	(86.9-127.0)	Male	26	63.3	41.1	(26.8-60.2)
Female	42	44.3	94.9	(68.4-128.2)	Female	22	55.0	40.0	(25.0-60.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	20	19.6	102.2	(62.4-157.9)	Male	11	16.0	68.6	(34.2-122.8)
Female	18	17.7	101.6	(60.2-160.6)	Female	15	13.9	108.3	(60.6-178.6)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	3.1	nc	(nc-nc)	Male	45	55.4	81.3	(59.3-108.8)
Female	318	383.6	82.9	(74.0-92.5)	Female	46	55.8	82.4	(60.3-109.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	25	15.4	161.9	(104.7-238.9)	Male	47	36.4	129.2	(94.9-171.8)
Female					Female	32	20.1	159.4	(109.0-225.0)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	134	137.3	97.6	(81.8-115.6)	Female	38	40.2	94.6	(66.9-129.8)
Female	165	155.0	106.4	(90.8-124.0)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	35	31.7	110.5	(76.9-153.6)
Male	30	26.1	115.1	(77.6-164.3)	Female	35	38.6	90.7	(63.2-126.2)
Female	5	8.4	59.3	(19.1-138.5)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	362	367.6	98.5	(88.6-109.2)
Male	9	9.0	100.4	(45.8-190.7)	<u>Stomach</u>				
Female	8	7.5	107.0	(46.1-210.8)	Male	38	24.5	155.1	(109.7-212.9)
<u>Kidney & Renal Pelvis</u>					Female	19	17.5	108.5	(65.3-169.5)
Male	44	48.5	90.7	(65.9-121.8)	<u>Testis</u>				
Female	35	33.1	105.9	(73.7-147.3)	Male	12	14.3	83.8	(43.2-146.4)
<u>Larynx</u>					<u>Thyroid</u>				
Male	19	15.4	123.2	(74.2-192.4)	Male	13	16.7	77.8	(41.4-133.0)
Female	4	4.8	nc	(nc-nc)	Female	28	57.1	49.1	(32.6-70.9)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	39	36.0	108.4	(77.1-148.2)	Female	85	84.8	100.3	(80.1-124.0)
Female	23	30.8	74.7	(47.3-112.1)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	1355	1345.9	100.7	(95.4-106.2)
Male	40	23.6	169.5	(121.1-230.8)	Female	1294	1421.3	91.0	(86.1-96.1)
Female	14	10.0	140.4	(76.7-235.6)					
<u>Lung and Bronchus</u>									
Male	221	189.2	116.8	(101.9-133.2)					
Female	201	207.5	96.9	(83.9-111.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

New Braintree

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	0.9	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	1	0.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	3	3.6	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	1	1.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	1	0.3	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	1	0.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	4	3.5	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.1	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	<u>Testis</u>				
Female	0	0.3	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.3	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	10	12.9	77.8	(37.2-143.1)
Male	1	0.3	nc	(nc-nc)	Female	10	12.0	83.6	(40.0-153.8)
Female	1	0.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	0	1.7	nc	(nc-nc)					
Female	2	1.6	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

New Marlborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	2.1	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.4	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	4	6.1	nc	(nc-nc)	Female	3	0.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.2	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	2	2.8	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Female	4	2.1	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	0	0.6	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	8	8.1	98.9	(42.6-194.8)
Male	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.2	nc	(nc-nc)
Male	2	1.0	nc	(nc-nc)	<u>Testis</u>				
Female	0	0.5	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	0.3	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	2	0.9	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	0.7	nc	(nc-nc)	Female	0	1.4	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	25	27.9	89.7	(58.0-132.4)
Male	1	0.5	nc	(nc-nc)	Female	19	21.1	90.1	(54.2-140.7)
Female	0	0.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	2	3.8	nc	(nc-nc)					
Female	4	3.0	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

New Salem

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	1.2	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	3	3.9	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	4	1.6	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	0	0.4	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	4	4.9	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
Female	1	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.1	nc	(nc-nc)
Male	1	0.6	nc	(nc-nc)	<u>Testis</u>				
Female	1	0.3	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	2	0.7	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.4	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	13	16.7	78.0	(41.5-133.4)
Male	0	0.3	nc	(nc-nc)	Female	12	12.6	94.9	(49.0-165.8)
Female	0	0.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	3	2.2	nc	(nc-nc)					
Female	2	1.6	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;